16h
Medpage Today on MSNSome Psoriasis Biologics Better Than Others for Preventing Progression to PsAPsoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...
Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first ...
A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...
Knowing which kind of psoriasis you have helps you and your doctor make a treatment plan. Most people have only one type at a time. Experts believe psoriasis is an autoimmune disease.
Not a lot of people know about psoriasis which is why several myths and misconceptions about the condition continue to ...
More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...
Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu ...
A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.
Feb. 3, 2025 — Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the ...
The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...
The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results